Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair deficiencies. Academic Article

authors

  • Agarwal, Neeraj
  • Azad, Arun
  • Fay, Andre
  • Carles, Joan
  • Shore, Neal D.
  • Nordquist, Luke T.
  • Karsh, Lawrence, MD, FACS, CPI
  • Dunshee, Curtis
  • Ponnathapura Nandakumar, Srinand
  • Sullivan, Beth
  • Czibere, Akos
  • Wang, Fong
  • Fizazi, Karim

Publication Date

  • 2018

webpage

published in

start page

  • TPS5091

end page

  • TPS5091

volume

  • 36

issue

  • 15_suppl